DES vary according to stent scaffold material and design, drug content, and the polymer used for drug elution; however, several common clinical features are present. First, sirolimus- eluting stents, paclitaxel-eluting stents, and zotarolimus- eluting stents have been demonstrated in RCTs to be associ- ated with a reduced need for repeat revascularization and no increase in death or MI compared with BMS at 4 years follow-up.465 Everolimus-eluting stents have been demon- strated in RCTs to be associated with a lower need for repeat revascularization than paclitaxel-eluting stents, and, by infer- ence, a lower risk for repeat revascularization than BMS,466,467 with no increase in death or MI at 2-year follow-up.468 Second, each of these stents is presumed to be associated with delayed healing based on pathologic studies and longer periods of risk for thrombosis compared with BMS and require longer duration of DAPT.469 In the RCTs that led to the US Food and Drug Administration (FDA) approval of these stents, the recommended minimum duration of DAPT therapy was 3 to 6 months. Recently, the consensus of clinical practice has been 12 months of DAPT following DES implantation to avoid late (after 30 days) thrombosis,208 based on observational studies of paclitaxel-eluting stents and sirolimus-eluting stents that indicate lower risk of late stent thrombosis with 6 months of therapy.212 Extending DAPT beyond 1 year is considered reasonable by some practitioners based on observational data analysis,212 but RCTs to deter- mine whether longer DAPT is associated with reduction in stent thrombosis risk have not been completed. Finally, DES therapy is more expensive than BMS. 